Please login to the form below

Not currently logged in
Email:
Password:

heart failure therapy

This page shows the latest heart failure therapy news and features for those working in and with pharma, biotech and healthcare.

Blow for Entresto in latest heart failure trial

Blow for Entresto in latest heart failure trial

hospitalisations. The news is unfortunate for Novartis, as heart failure remains an area of high unmet need, affecting around 26 million people worldwide. ... Novartis has faced increasing competition in the heart failure therapy area of late, with

Latest news

More from news
Approximately 0 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    the heart, and its proposed benefits have been backed up in clinical trials. ... failure by 18%  compared to placebo when given on top of standard HF therapy.

  • Pharma deals in April 2015 Pharma deals in April 2015

    uniQure has licensed its proprietary gene therapy programme for congestive heart failure, that is hoped will restore the heart's ability to synthesise S100A1, a calcium sensor and master regulator of ... to become available for common diseases such as

  • Pharma deals during October 2013 Pharma deals during October 2013

    heart failure (phase IIb). 75. ... 75. Trevena. TRV027, GPCR biased ligand for acute heart failure (phase II).

More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    Kapusta had previously served as the gene therapy specialist's interim chief executive since September last year, as well as chief financial officer since January 2015. ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics